|
Model
|
eGFR
|
Ln-UAE
|
LGI
|
ED
|
|---|
|
β
|
95% CI
|
p value
|
β
|
95% CI
|
p value
|
β
|
95% CI
|
p value
|
β
|
95% CI
|
p value
|
|---|
|
MMP-1
|
|
1
|
−4.15
|
−6.58; −1.73
|
0.001
|
−0.01
|
−0.13; 0.11
|
0.912
|
0.14
|
0.02; 0.25
|
0.017
|
−0.07
|
−0.18; 0.05
|
0.249
|
|
2
|
−2.90
|
−5.22; −0.57
|
0.015
|
−0.03
|
−0.14; 0.08
|
0.588
|
0.11
|
0.00; 0.22
|
0.045
|
−0.12
|
−0.23; −0.01
|
0.031
|
|
MMP-2
|
|
1
|
−11.9
|
−14.27; −9.56
|
<0.001
|
0.29
|
0.16; 0.41
|
<0.001
|
−0.02
|
−0.14; 0.10
|
0.770
|
0.06
|
−0.06; 0.18
|
0.333
|
|
2
|
−10.1
|
−12.48; −7.64
|
<0.001
|
0.19
|
0.07; 0.32
|
0.002
|
0.02
|
−0.11; 0.15
|
0.759
|
0.07
|
−0.06; 0.19
|
0.318
|
|
MMP-3
|
|
1
|
−12.6
|
−15.37; −9.92
|
<0.001
|
0.28
|
0.13; 0.42
|
<0.001
|
0.02
|
−0.12; 0.16
|
0.779
|
0.02
|
−0.12; 0.16
|
0.792
|
|
2
|
−10.3
|
−13.05; −7.64
|
<0.001
|
0.16
|
0.02; 0.30
|
0.022
|
0.05
|
−0.09; 0.19
|
0.513
|
0.02
|
−0.12; 0.16
|
0.818
|
|
MMP-9
|
|
1
|
−0.72
|
−3.13; 1.70
|
0.559
|
0.02
|
−0.09; 0.14
|
0.708
|
0.28
|
0.18; 0.39
|
<0.001
|
0.05
|
−0.06; 0.16
|
0.347
|
|
2
|
−0.14
|
−2.56; 2.29
|
0.912
|
0.02
|
−0.10; 0.13
|
0.781
|
0.22
|
0.11; 0.33
|
<0.001
|
−0.03
|
−0.15; 0.08
|
0.580
|
|
MMP-10
|
|
1
|
−6.45
|
−8.70; −4.19
|
<0.001
|
0.08
|
−0.03; 0.20
|
0.146
|
0.14
|
0.03; 0.25
|
0.010
|
0.13
|
0.03; 0.24
|
0.015
|
|
2
|
−6.18
|
−8.32; −4.03
|
<0.001
|
0.11
|
0.00; 0.21
|
0.045
|
0.09
|
−0.02; 0.19
|
0.104
|
0.09
|
−0.02; 0.19
|
0.110
|
|
TIMP-1
|
|
1
|
−10.2
|
−12.65; −7.82
|
<0.001
|
0.26
|
0.14; 0.39
|
<0.001
|
0.30
|
0.19; 0.42
|
<0.001
|
0.23
|
0.11; 0.35
|
<0.001
|
|
2
|
−8.13
|
−10.58; −5.68
|
<0.001
|
0.17
|
0.05; 0.29
|
0.005
|
0.33
|
0.21; 0.45
|
<0.001
|
0.22
|
0.10; 0.34
|
<0.001
|
- The standardized regression coefficient β represents the difference in eGFR (in ml/min/1.73 m2), lnUAE (in mg/24 h), LGI (in SD) or ED (in SD) per 1 SD increase in lnMMP-1, -2, -3, -9, and -10 and lnTIMP-1
-
MMP matrix metalloproteinase, TIMP-1 tissue inhibitor of metalloproteinase-1
-
Model 1 adjusted for age, sex, HbA1c, nephropathy-no nephropathy status and duration of diabetes
-
Model 2 Model 1 + MAP, BMI, smoking status, total cholesterol, use of antihypertensive agents and continuation of medication use at baseline
